These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31038370)

  • 21. Body dysmorphic disorder.
    Bjornsson AS; Didie ER; Phillips KA
    Dialogues Clin Neurosci; 2010; 12(2):221-32. PubMed ID: 20623926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of pharmacotherapy for obsessive-compulsive disorder may lie in a better understanding of its heterogeneity.
    Brakoulias V
    Expert Opin Pharmacother; 2014 Jul; 15(10):1321-3. PubMed ID: 24866422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
    Hollander E; Allen A; Kwon J; Aronowitz B; Schmeidler J; Wong C; Simeon D
    Arch Gen Psychiatry; 1999 Nov; 56(11):1033-9. PubMed ID: 10565503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
    Phillips KA
    Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of epidemiology, clinical presentation, diagnosis, and treatment of common primary psychiatric causes of cutaneous disease.
    Krooks JA; Weatherall AG; Holland PJ
    J Dermatolog Treat; 2018 Jun; 29(4):418-427. PubMed ID: 29052453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mental Disorders: Obsessive-Compulsive Disorder and Body Dysmorphic Disorder.
    Morgan S
    FP Essent; 2020 Aug; 495():17-22. PubMed ID: 32757562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of the pharmacological options for pediatric obsessive-compulsive disorder.
    Marazziti D; Pozza A
    Expert Opin Pharmacother; 2022 Nov; 23(16):1793-1800. PubMed ID: 36310087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
    Schneier FR; Feusner J; Wheaton MG; Gomez GJ; Cornejo G; Naraindas AM; Hellerstein DJ
    J Psychiatr Res; 2023 May; 161():364-370. PubMed ID: 37004409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapeutic Strategies and New Targets in OCD.
    Pittenger C
    Curr Top Behav Neurosci; 2021; 49():331-384. PubMed ID: 33751503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
    J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive-behavioral therapy for youth with body dysmorphic disorder: current status and future directions.
    Phillips KA; Rogers J
    Child Adolesc Psychiatr Clin N Am; 2011 Apr; 20(2):287-304. PubMed ID: 21440856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do all obsessive-compulsive disorder subtypes respond to medication?
    Grados M; Riddle MA
    Int Rev Psychiatry; 2008 Apr; 20(2):189-93. PubMed ID: 18386211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of body dysmorphic disorder and its presentation in different clinical settings.
    Mufaddel A; Osman OT; Almugaddam F; Jafferany M
    Prim Care Companion CNS Disord; 2013; 15(4):. PubMed ID: 24392251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Body dysmorphic disorder: Symptoms, prevalence, assessment and treatment].
    Hardardottir H; Hauksdottir A; Bjornsson AS
    Laeknabladid; 2019 Mar; 105(3):125-131. PubMed ID: 30806630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
    Poppe C; Müller ST; Greil W; Walder A; Grohmann R; Stübner S
    J Affect Disord; 2016 Aug; 200():89-96. PubMed ID: 27130958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.